Literature DB >> 22969861

microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3.

Jaeku Kang1, Soo Young Lee, Sun Young Lee, Young Jin Kim, Jae Yong Park, Sun Jung Kwon, Moon Jun Na, Eun Jin Lee, Hyo Sung Jeon, Ji Woong Son.   

Abstract

microRNAs (miRNAs) play a significant role in cancer development and progression by regulating the expression of proto-oncogenes or tumor suppressor genes. Our previous study using microarrays demonstrated that miR-99b was downregulated in patients with lung cancer. To assess whether or not miR-99b has a functional role in lung cancer, we determined the expression of miR-99b and fibroblast growth factor receptor 3 (FGFR3), which is a predicted target of miR-99b in public algorithms in human lung cancer tissues. miR-99b was downregulated and FGFR3 was upregulated in lung cancer patients. We demonstrated that the overexpression of miR-99b induced a reduction in FGFR3 expression and confirmed the target specificity between miR-99b and the FGFR3 3'-untranslated region by luciferase reporter assay. In addition, the growth rate in miR-99b precursor-treated cells was lower compared to the negative controls. Taken together, these results suggest that miR-99b may be a tumor suppressor through the downregulation of FGFR3. miR-99b may be a potent tumor suppressor and may be a potential therapeutic tool for patients with lung cancer.

Entities:  

Year:  2011        PMID: 22969861      PMCID: PMC3438617          DOI: 10.3892/etm.2011.366

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  31 in total

Review 1.  Roles of fibroblast growth factor receptors in carcinogenesis.

Authors:  Ellen Margrethe Haugsten; Antoni Wiedlocha; Sjur Olsnes; Jørgen Wesche
Journal:  Mol Cancer Res       Date:  2010-10-13       Impact factor: 5.852

2.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

3.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

Authors:  C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

4.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Authors:  Michela Garofalo; Gianpiero Di Leva; Giulia Romano; Gerard Nuovo; Sung-Suk Suh; Apollinaire Ngankeu; Cristian Taccioli; Flavia Pichiorri; Hansjuerg Alder; Paola Secchiero; Pierluigi Gasparini; Arianna Gonelli; Stefan Costinean; Mario Acunzo; Gerolama Condorelli; Carlo Maria Croce
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

5.  MicroRNAs modulate hematopoietic lineage differentiation.

Authors:  Chang-Zheng Chen; Ling Li; Harvey F Lodish; David P Bartel
Journal:  Science       Date:  2003-12-04       Impact factor: 47.728

6.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer.

Authors:  Aurora Esquela-Kerscher; Phong Trang; Jason F Wiggins; Lubna Patrawala; Angie Cheng; Lance Ford; Joanne B Weidhaas; David Brown; Andreas G Bader; Frank J Slack
Journal:  Cell Cycle       Date:  2008-03-03       Impact factor: 4.534

7.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

Review 8.  The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Scott A Kono; Marianne E Marshall; Kathryn E Ware; Lynn E Heasley
Journal:  Drug Resist Updat       Date:  2009-06-04       Impact factor: 18.500

9.  Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

Authors:  F R Lamont; D C Tomlinson; P A Cooper; S D Shnyder; J D Chester; M A Knowles
Journal:  Br J Cancer       Date:  2010-11-30       Impact factor: 7.640

10.  FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.

Authors:  D C Tomlinson; O Baldo; P Harnden; M A Knowles
Journal:  J Pathol       Date:  2007-09       Impact factor: 7.996

View more
  25 in total

1.  MicroRNA-140-3p inhibits proliferation, migration and invasion of lung cancer cells by targeting ATP6AP2.

Authors:  Xiao-Mei Kong; Ge-Hong Zhang; Yun-Kui Huo; Xiao-Hong Zhao; Da-Wei Cao; Shu-Fang Guo; Ai-Min Li; Xin-Ri Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3.

Authors:  Jie Luo; Bin Chen; Xian-Xiu Ji; Song-Wen Zhou; Di Zheng
Journal:  Tumour Biol       Date:  2015-08-28

3.  The FGF/FGFR axis as a therapeutic target in breast cancer.

Authors:  Nicholas Brady; Polly Chuntova; Lindsey K Bade; Kathryn L Schwertfeger
Journal:  Expert Rev Endocrinol Metab       Date:  2013-07

4.  miRNA-124 down-regulates SOX8 expression and suppresses cell proliferation in non-small cell lung cancer.

Authors:  Chao Xie; Yunwei Han; Yi Liu; Lei Han; Jie Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.

Authors:  Brittany C Parker; Matti J Annala; David E Cogdell; Kirsi J Granberg; Yan Sun; Ping Ji; Xia Li; Joy Gumin; Hong Zheng; Limei Hu; Olli Yli-Harja; Hannu Haapasalo; Tapio Visakorpi; Xiuping Liu; Chang-Gong Liu; Raymond Sawaya; Gregory N Fuller; Kexin Chen; Frederick F Lang; Matti Nykter; Wei Zhang
Journal:  J Clin Invest       Date:  2013-01-09       Impact factor: 14.808

6.  Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2+ breast cancer.

Authors:  Joseph T Decker; Matthew S Hall; Rachel B Blaisdell; Kallen Schwark; Jacqueline S Jeruss; Lonnie D Shea
Journal:  Biotechnol Bioeng       Date:  2018-08-02       Impact factor: 4.530

7.  miRNA-124 down-regulates SOX8 expression and suppresses cell proliferation in non-small cell lung cancer.

Authors:  Chao Xie; Yunwei Han; Yi Liu; Lei Han; Jie Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

8.  The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma.

Authors:  Lucy F Stead; Stefano Berri; Henry M Wood; Philip Egan; Caroline Conway; Catherine Daly; Kostas Papagiannopoulos; Pamela Rabbitts
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

9.  Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3.

Authors:  Yongjun Yin; Tomoko Betsuyaku; Joel R Garbow; Jinbai Miao; Ramaswamy Govindan; David M Ornitz
Journal:  Cancer Res       Date:  2013-07-18       Impact factor: 12.701

10.  miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway.

Authors:  Li Wang; Lihua Chang; Zhaorong Li; Qing Gao; Dongge Cai; Yingfang Tian; Lingxia Zeng; Mu Li
Journal:  Med Oncol       Date:  2014-03-26       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.